TEVA vs. INSM

Last updated Jun 9, 2026

TEVA (Teva Pharmaceutical Industries Limited) and INSM (Insmed Incorporated) are both stocks. Both are in the Healthcare sector — TEVA in Drug Manufacturers - Specialty & Generic, INSM in Biotechnology. Over the past 10 years, TEVA returned -4.15%/yr vs 24.09%/yr for INSM. At a 0.21 correlation, their price movements are largely independent.

Performance

TEVA vs. INSM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Teva Pharmaceutical Industries Limited (TEVA) and Insmed Incorporated (INSM). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, TEVA achieves a 6.57% return, which is significantly higher than INSM's -45.89% return. Over the past 10 years, TEVA has underperformed INSM with an annualized return of -4.15%, while INSM has yielded a comparatively higher 24.09% annualized return.

TEVA

• 1D: -2.72%
• 1M: -6.91%
• YTD: 6.57%
• 6M: 17.40%
• 1Y: 87.17%
• 3Y*: 65.55%
• 5Y*: 25.39%
• 10Y*: -4.15%

INSM

• 1D: -0.05%
• 1M: -7.08%
• YTD: -45.89%
• 6M: -52.09%
• 1Y: 27.91%
• 3Y*: 68.17%
• 5Y*: 27.84%
• 10Y*: 24.09%

*Multi-year figures are annualized to reflect compound growth (CAGR)

TEVA vs. INSM - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
TEVA Teva Pharmaceutical Industries Limited	6.57%	41.61%	111.11%	14.47%	13.86%	-16.99%	-1.53%	-36.45%	-18.63%	-46.18%
INSM Insmed Incorporated	-45.89%	152.09%	122.78%	55.11%	-26.65%	-18.17%	39.41%	82.01%	-57.92%	135.68%

Correlation

The correlation between TEVA and INSM is 0.23, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.23
Correlation (3Y) Calculated over the trailing 3-year period	0.18
Correlation (5Y) Calculated over the trailing 5-year period	0.26
Correlation (10Y) Calculated over the trailing 10-year period	0.27
Correlation (All Time) Calculated using the full available price history since Jun 2, 2000	0.21

Fundamentals

Market Cap TEVA : $39.21B INSM : $20.29B
EPS TEVA : $1.34 INSM : -$5.71
PS Ratio TEVA : 2.24 INSM : 23.84
PB Ratio TEVA : 4.76 INSM : 28.79
Total Revenue (TTM) TEVA : $17.35B INSM : $819.56M
Gross Profit (TTM) TEVA : $9.03B INSM : $668.55M
EBITDA (TTM) TEVA : $3.05B INSM : -$1.14B

Return for Risk

TEVA vs. INSM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TEVA

TEVA Risk / Return Rank: 90
TEVA Sharpe Ratio Rank: 91
TEVA Sortino Ratio Rank: 92
TEVA Omega Ratio Rank: 91
TEVA Calmar Ratio Rank: 89
TEVA Martin Ratio Rank: 89

INSM

INSM Risk / Return Rank: 57
INSM Sharpe Ratio Rank: 58
INSM Sortino Ratio Rank: 57
INSM Omega Ratio Rank: 62
INSM Calmar Ratio Rank: 54
INSM Martin Ratio Rank: 55

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TEVA vs. INSM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Teva Pharmaceutical Industries Limited (TEVA) and Insmed Incorporated (INSM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	TEVA	INSM	Difference
Sharpe ratio: Return per unit of total volatility	2.25	0.47	+1.78
Sortino ratio: Return per unit of downside risk	3.42	1.09	+2.33
Omega ratio: Gain probability vs. loss probability	1.43	1.17	+0.26
Calmar ratio: Return relative to maximum drawdown	4.02	0.51	+3.52
Martin ratio: Return relative to average drawdown	10.94	1.23	+9.70
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

TEVA vs. INSM - Sharpe Ratio Comparison

The current TEVA Sharpe Ratio is 2.25, which is higher than the INSM Sharpe Ratio of 0.47. The chart below compares the historical Sharpe Ratios of TEVA and INSM, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	TEVA	INSM	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.25	0.47	+1.78
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.59	0.38	+0.21
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.09	0.31	-0.40
Sharpe Ratio (All Time) Calculated using the full available price history	0.31	-0.02	+0.34

Drawdowns

TEVA vs. INSM - Drawdown Comparison

The maximum TEVA drawdown since its inception was -90.89%, smaller than the maximum INSM drawdown of -98.65%. Use the drawdown chart below to compare losses from any high point for TEVA and INSM.

Drawdown Indicators

	TEVA	INSM	Difference
Max Drawdown Largest peak-to-trough decline	-90.89%	-98.65%	+7.76%
Max Drawdown (1Y) Largest decline over 1 year	-21.79%	-55.46%	+33.67%
Max Drawdown (3Y) Largest decline over 3 years	-43.70%	-55.46%	+11.76%
Max Drawdown (5Y) Largest decline over 5 years	-43.70%	-55.46%	+11.76%
Max Drawdown (10Y) Largest decline over 10 years	-88.41%	-64.84%	-23.57%
Current Drawdown Current decline from peak	-50.84%	-55.46%	+4.62%
Average Drawdown Average peak-to-trough decline	-32.00%	-86.11%	+54.11%
Ulcer Index Depth and duration of drawdowns from previous peaks	8.00%	22.66%	-14.66%

Volatility

TEVA vs. INSM - Volatility Comparison

The current volatility for Teva Pharmaceutical Industries Limited (TEVA) is 9.18%, while Insmed Incorporated (INSM) has a volatility of 18.58%. This indicates that TEVA experiences smaller price fluctuations and is considered to be less risky than INSM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	TEVA	INSM	Difference
Volatility (1M) Calculated over the trailing 1-month period	9.18%	18.58%	-9.40%
Volatility (6M) Calculated over the trailing 6-month period	23.54%	45.00%	-21.46%
Volatility (1Y) Calculated over the trailing 1-year period	38.97%	59.24%	-20.27%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	42.94%	72.76%	-29.82%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	47.34%	78.47%	-31.13%

Dividends

TEVA vs. INSM - Dividend Comparison

Neither TEVA nor INSM has paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
INSM Insmed Incorporated	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
TEVA Teva Pharmaceutical Industries Limited	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3.88%	3.19%	1.77%

Financials

TEVA vs. INSM - Profitability Comparison

The chart below illustrates the profitability comparison between Teva Pharmaceutical Industries Limited and Insmed Incorporated over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

TEVA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Teva Pharmaceutical Industries Limited reported a gross profit of 1.97B and revenue of 3.98B. Therefore, the gross margin over that period was 49.5%.

INSM - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Insmed Incorporated reported a gross profit of 258.54M and revenue of 305.96M. Therefore, the gross margin over that period was 84.5%.

TEVA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Teva Pharmaceutical Industries Limited reported an operating income of 652.00M and revenue of 3.98B, resulting in an operating margin of 16.4%.

INSM - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Insmed Incorporated reported an operating income of -198.20M and revenue of 305.96M, resulting in an operating margin of -64.8%.

TEVA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Teva Pharmaceutical Industries Limited reported a net income of 369.00M and revenue of 3.98B, resulting in a net margin of 9.3%.

INSM - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Insmed Incorporated reported a net income of -163.56M and revenue of 305.96M, resulting in a net margin of -53.5%.

Frequently Asked Questions

Can I hold both TEVA and INSM in my portfolio?

TEVA and INSM have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, TEVA or INSM?

INSM has higher volatility (18.58%) compared to TEVA (9.18%). In terms of maximum drawdown, TEVA dropped -90.89% vs INSM's -98.65%.

Which has better risk-adjusted returns?

TEVA currently has the higher Sharpe Ratio (2.25 vs 0.47), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.